Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to…
Pharmaceuticals, Biotechnology and Life Sciences
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to…
29% Increase in Product and Services Revenue; 26% Increase in Total RevenueWINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) — Kane…
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology…
PETALUMA, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition…
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual MeetingWESTPORT, Conn., Nov. 28, 2023 (GLOBE…
Strategic Plan to Prevent Conversion into 100 Million Common Unrestricted Shares, Enhancing Shareholder ValueMELBOURNE, Fla., Nov. 28, 2023 (GLOBE NEWSWIRE)…
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this…
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells…
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated…
– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective…